Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.44

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.44 and traded as high as $6.03. Capricor Therapeutics shares last traded at $5.93, with a volume of 276,550 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald initiated coverage on Capricor Therapeutics in a report on Friday, January 5th. They issued an “overweight” rating and a $8.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Friday, March 1st. Finally, StockNews.com upgraded Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th.

Capricor Therapeutics Stock Up 1.2 %

The firm has a market cap of $186.80 million, a P/E ratio of -6.82 and a beta of 3.99. The firm has a fifty day moving average of $5.44 and a 200-day moving average of $4.26.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.21. The firm had revenue of $12.09 million for the quarter, compared to analyst estimates of $5.80 million. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. On average, equities analysts forecast that Capricor Therapeutics Inc will post -0.83 EPS for the current year.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 1,165,404 shares of the biotechnology company’s stock valued at $5,699,000 after buying an additional 13,086 shares during the period. Northern Trust Corp raised its stake in Capricor Therapeutics by 21.2% in the fourth quarter. Northern Trust Corp now owns 127,229 shares of the biotechnology company’s stock valued at $622,000 after buying an additional 22,269 shares during the period. Jump Financial LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $258,000. Citigroup Inc. bought a new stake in Capricor Therapeutics in the third quarter valued at approximately $211,000. Finally, GSA Capital Partners LLP raised its stake in Capricor Therapeutics by 144.9% in the third quarter. GSA Capital Partners LLP now owns 43,805 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 25,915 shares during the period. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.